Cargando…
The case for inhibiting p38 mitogen-activated protein kinase in heart failure
This minireview discusses the evidence that the inhibition of p38 mitogen-activated protein kinases (p38 MAPKs) maybe of therapeutic value in heart failure. Most previous experimental studies, as well as past and ongoing clinical trials, have focussed on the role of p38 MAPKs in myocardial infarctio...
Autores principales: | Arabacilar, Pelin, Marber, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428223/ https://www.ncbi.nlm.nih.gov/pubmed/26029107 http://dx.doi.org/10.3389/fphar.2015.00102 |
Ejemplares similares
-
Redox-dependent dimerization of p38α mitogen-activated protein kinase with mitogen-activated protein kinase kinase 3
por: Bassi, Rekha, et al.
Publicado: (2017) -
Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD
por: Yu, Haichuan, et al.
Publicado: (2022) -
The activation of p38alpha, and not p38beta, mitogen-activated protein kinase is required for ischemic preconditioning
por: Sicard, Pierre, et al.
Publicado: (2010) -
Higenamine Attenuates Neuropathic Pain by Inhibition of NOX2/ROS/TRP/P38 Mitogen-Activated Protein Kinase/NF-ĸB Signaling Pathway
por: Yang, Bing, et al.
Publicado: (2021) -
Mechanism and consequence of the autoactivation p38α Mitogen-activated Protein Kinase promoted by TAB1
por: DeNicola, Gian Felice, et al.
Publicado: (2013)